| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 39,862 | 13,530 |
| Net increase in cash and cash equivalents | 16,553 | -3,815 |
| Cash and cash equivalents at beginning of period | 26,142 | - |
| Cash and cash equivalents at end of period | 42,695 | - |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)